The effects of dulaglutide and a calorie-restricted diet (CRD) on visceral adipose tissue (VAT) and metabolic profiles in polycystic ovary syndrome (PCOS) have not been extensively investigated. In this study, we investigated whether dulaglutide combined with CRD could further reduce VAT and promote clinical benefits as compared with a CRD regimen alone in overweight or obese PCOS-affected women. Between May 2021 and May 2022, this single-center, randomized, controlled, open-label clinical trial was conducted. Overall, 243 participants with PCOS were screened, of which 68 overweight or obese individuals were randomly randomized to undergo dulaglutide combined with CRD treatment (n = 35) or CRD treatment alone (n = 33). The duration of intervention was set as the time taken to achieve a 7% weight loss goal from baseline body weight, which was restricted to 6 months. The primary endpoint was the difference in the change in VAT area reduction between the groups. The secondary endpoints contained changes in menstrual frequency, metabolic profiles, hormonal parameters, liver fat, and body composition. As compared with the CRD group, the dulaglutide + CRD group had a considerably shorter median time to achieve 7% weight loss. There was no significant between-group difference in area change of VAT reduction (−0.97 cm2, 95% confidence interval from −14.36 to 12.42, p = 0.884). As compared with CRD alone, dulaglutide + CRD had significant advantages in reducing glycated hemoglobin A1c and postprandial plasma glucose levels. The results of the analyses showed different changes in menstruation frequency, additional metabolic profiles, hormonal markers, liver fat, and body composition between the two groups did not differ significantly. Nausea, vomiting, constipation, and loss of appetite were the main adverse events of dulaglutide. These results emphasize the value of dietary intervention as the first line of treatment for PCOS-affected women, while glucagon-like peptide 1 receptor agonist therapy provides an efficient and typically well tolerated adjuvant therapy to aid in reaching weight targets based on dietary therapy in the population of overweight/obese PCOS-affected women.
Objective. To explore the regularity of fetal lung development of pregnant women with gestational diabetes mellitus (GDM) with satisfactory blood glucose control and the clinical analysis with pregnancy outcome. Methods. 120 GDM pregnant women with satisfactory blood glucose control (GDM group) and 200 normal pregnant women undergoing prenatal examination (Control group) from 31 to 38 + 6 weeks of gestation were included. The two groups of pregnant women were divided into 8 time periods according to the gestational age, respectively. The parameters of Doppler flow velocity curve of fetal main pulmonary artery, diameter lines of fetal lung development, mode of delivery, neonatal weight, neonatal asphyxia, neonatal respiratory distress syndrome (NRDS), and neonatal pneumonia were, respectively, compared and analyzed between the two groups. Results. Acceleration time (AT) and AT/ejection time (AT/ET) were positively correlated with gestational age, and AT/ET showed stronger correlation than AT, while no significant difference in AT and AT/ET between the two groups ( P > 0.05 ). There was a positive correlation between the diameter of fetal lung development and gestational age, but there was no significant difference between the two groups ( P > 0.05 ). In addition, there was no significant difference between the two groups in fetal delivery mode, neonatal weight, neonatal asphyxia, NRDS, and neonatal pneumonia ( P > 0.05 ). Conclusion. AT/ET may be a potential index to evaluate fetal lung maturity. There was no difference in fetal lung development and neonatal birth outcome between pregnant women with satisfactory GDM blood glucose control and the normal pregnant women. The pregnancy of GDM pregnant women lasts until the end of 37∼38 weeks, and the neonatal incidence rate is decreased. The key is to manipulate the blood glucose in the normal range.
The diagnostic performance of VTQ and VTIQ was moderate to good for solid breast tumors. Although both methods have higher sensitivities in tumors≥10 mm, their overall diagnostic performance was similar for all sizes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.